Editor's Note: DownRange received a submission request for an article based on a PLoS medical journal study about head and neck cancer immunotherapy (ZBP1 protein and CD8+ T cells). This has zero relevance to firearms, carry law, gun rights, or Second Amendment policy. We don't publish content outside our lane, period. Our readers come here for gun news—not cancer research.
If you have actual 2A news, case law updates, legislative action, or industry developments worth covering, send it our way. We'll treat it with the specificity and straight talk it deserves.
